GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA) ("STAAR†), the manufacturer of the Implantable Collamer® Lens (ICL), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Alcon's acquisition of STAAR, expired at 11:59 p.m. ET on September 29, 2025. As previously announced,. ...

Group 1 - Halper Sadeh LLC is investigating STAAR Surgical Company for potential violations related to its sale to Alcon at $28.00 per share in cash [1] - CyberArk Software Ltd. is being investigated for its sale to Palo Alto Networks for $45.00 in cash and 2.2005 shares of Palo Alto common stock for each CyberArk share [2] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Viewpoint - Kaskela Law LLC is investigating the fairness of the proposed buyout of STAAR Surgical Company by Alcon at a price of $28.00 per share, which is significantly lower than the company's recent trading prices and 52-week high [1][3]. Group 1: Buyout Details - On August 5, 2025, STAAR announced its agreement to be acquired by Alcon for $28.00 per share in cash [2]. - Many STAAR shareholders purchased their shares at prices above $30.00, indicating potential dissatisfaction with the buyout price [2]. Group 2: Investigation Focus - The investigation aims to determine if STAAR investors are receiving adequate monetary consideration for their shares [3]. - It will also assess whether the company's officers or directors breached their fiduciary duties or violated securities laws in agreeing to the buyout price [3]. Group 3: Shareholder Impact - The proposed buyout price of $28.00 per share is notably lower than STAAR's 52-week high of $38.60 per share, raising concerns among investors [3].

Core Insights - STAAR Surgical Company, a leader in phakic IOLs, announced the expiration of the 45-day "window shop" period related to its merger agreement with Alcon, with no competing acquisition proposals received [1] Company Summary - STAAR Surgical Company specializes in the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction [1] - The merger agreement with Alcon affiliates remains intact following the expiration of the "window shop" period [1] Industry Context - The expiration of the "window shop" period indicates a stable environment for STAAR Surgical's merger with Alcon, suggesting confidence in the deal's progression [1]

Core Viewpoint - Yunqi Capital, a 5.1% shareholder of Staar Surgical Company, opposes the proposed sale of the company to Alcon based on the terms announced on August 5 [1] Group 1 - Yunqi Capital believes the sale price of $28 per share is inadequate [1]

Core Viewpoint - Yunqi Capital Limited, a 5.1% shareholder of STAAR Surgical Company, opposes the proposed sale of STAAR to Alcon Inc. on the terms announced on August 5, 2025 [1] Group 1 - Yunqi Capital has released an open letter to fellow STAAR shareholders detailing the reasons for its opposition to the transaction [1]

In conjunction with the definitive proxy filing, Staar (STAA) is mailing the following letter to Staar stockholders: “On August 5, 2025, we announced that STAAR Surgical Company entered into a definitive merger agreement to be acquired by Alcon (ALC) for $28.00 per share in cash. STAAR will hold a virtual Special Meeting of Stockholders on October 23 at 8:30 a.m. to ask for your vote to adopt the merger agreement. The STAAR Board of Directors unanimously determined that the proposed merger with Alcon is in ...

Core Viewpoint - The Ademi Firm is investigating STAAR for potential breaches of fiduciary duty and other legal violations related to its transaction with Alcon Inc, where STAAR shareholders will receive $28 per share in cash, valuing the transaction at approximately $[1] Group 1 - The investigation by the Ademi Firm focuses on possible breaches of fiduciary duty by STAAR in its dealings with Alcon Inc [1] - Shareholders of STAAR are set to receive $28 per share in cash as part of the transaction [1] - The total valuation of the transaction is approximately $[1]

Core Insights - The article highlights the ongoing high activity in mergers and acquisitions (M&A) within the global medical device sector in 2025, driven by technology, cross-regional expansion, and supply chain integration [2][5][56] Group 1: M&A Trends and Key Transactions - In 2025, significant M&A activities are observed, including a $17.5 billion acquisition by Waters of BD Life Sciences, which aims to create a comprehensive diagnostic platform [29][32] - Alcon has been particularly active in the ophthalmology sector, completing multiple acquisitions to strengthen its full-chain capabilities from surgical to non-surgical solutions [5][6][11] - The cardiovascular and neuro-interventional sectors are seeing a shift towards less invasive treatments and diversified therapeutic approaches, including non-drug solutions [12][30] Group 2: Sector-Specific Insights - The ophthalmology market is experiencing increased concentration, with Alcon's strategy focusing on a comprehensive technology loop covering refractive surgery, cataracts, retinal diseases, and corneal regeneration [5][11] - The cardiovascular and neuro-interventional M&A activities are characterized by a focus on reducing trauma and recovery time, with innovations like ultrasound renal denervation and non-drug thrombectomy gaining traction [12][30] - The production and supply chain capabilities are being enhanced through acquisitions of key components and materials, which are crucial for maintaining delivery reliability and optimizing profit structures [20][31] Group 3: AI and Precision Diagnostics - The AI and precision diagnostics segment is witnessing strategic acquisitions that enhance high-margin business lines and clinical authority, with notable transactions like Waters acquiring BD [28][32] - The integration of AI technologies into clinical applications is progressing, with companies focusing on data assets and algorithm platforms to enhance diagnostic accuracy and market competitiveness [44][55] Group 4: Women's Health and Specialty Surgery - The women's health and specialty surgery sectors are characterized by high margins and strong brand reliance, with acquisitions focusing on specific surgical pathways that are difficult to replace [37][43] - Companies like Hologic are expanding their portfolios to cover the entire patient journey from diagnosis to treatment, enhancing customer loyalty and repeat business [42][56] Group 5: Future Outlook and Strategic Implications - The M&A landscape in 2025 reflects a strategic repositioning of companies to adapt to clinical trends and market demands, with a focus on comprehensive coverage of treatment pathways and supply chain security [53][55] - The article emphasizes the importance of aligning technology and market positioning early to capitalize on potential acquisition opportunities and achieve high valuations [55][56]

Core Insights - Staar Surgical's international revenue performance is critical for assessing its financial resilience and growth prospects [1][2][3] Group 1: Financial Performance - The company's total revenue for the quarter was $44.32 million, a decline of 55.2% year over year [4] - Other International contributed $18.18 million, accounting for 41% of total revenue, which was a surprise of -24.34% compared to the consensus estimate of $24.03 million [5] - Japan generated $10.92 million, representing 24.6% of total revenue, with a positive surprise of +8.28% compared to the projected $10.08 million [6] - China accounted for 12% of total revenue, translating to $5.3 million, with a significant surprise of +454.87% against the expected $0.96 million [7] Group 2: Future Revenue Predictions - For the current fiscal quarter, analysts anticipate total revenues of $89.27 million, reflecting a 0.8% increase year over year [8] - Expected revenue contributions for the current quarter are 23.8% from Other International ($21.26 million), 12.8% from Japan ($11.38 million), and 54.2% from China ($48.36 million) [8] - For the full year, total revenue is projected to be $258.21 million, down 17.7% from the previous year, with specific contributions from Other International (36.1%), Japan (17.3%), and China (36.9%) [9] Group 3: Market Context - Staar Surgical's reliance on international markets presents both opportunities and challenges, necessitating close monitoring of international revenue trends [10] - The interconnected global economy and geopolitical factors are increasingly influencing earnings predictions for companies with overseas operations [10][11]